These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19487439)

  • 21. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model.
    Maglio D; Banevicius MA; Sutherland C; Babalola C; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):276-80. PubMed ID: 15616306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
    Gebru E; Damte D; Choi MJ; Lee SJ; Kim YH; Park SC
    Vet Microbiol; 2012 Jan; 154(3-4):384-94. PubMed ID: 21893387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
    Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
    J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.
    Pan AJ; Mei Q; Ye Y; Li HR; Liu B; Li JB
    J Antibiot (Tokyo); 2017 Feb; 70(2):166-173. PubMed ID: 27756910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.
    Blondeau JM
    Vet Dermatol; 2009 Oct; 20(5-6):383-96. PubMed ID: 20178475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.
    Lee SJ; Awji EG; Park NH; Park SC
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling.
    Liu X; Yang Q; Fan Y; Du Y; Lei L; Wang D; Liu Y
    BMC Vet Res; 2021 Jun; 17(1):212. PubMed ID: 34107961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli.
    Pellet T; Gicquel-Bruneau M; Sanders P; Laurentie M
    Res Vet Sci; 2006 Jun; 80(3):324-35. PubMed ID: 16126240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.
    LaPlante KL; Leonard SN; Andes DR; Craig WA; Rybak MJ
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2156-62. PubMed ID: 18411321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Nakai H; Sato T; Uno T; Furukawa E; Kawamura M; Takahashi H; Watanabe A; Fujimura S
    J Infect Chemother; 2018 Feb; 24(2):83-87. PubMed ID: 29290527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.
    Firsov AA; Strukova EN; Shlykova DS; Portnoy YA; Kozyreva VK; Edelstein MV; Dovzhenko SA; Kobrin MB; Zinner SH
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4956-62. PubMed ID: 23896481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
    Linde HJ; Lehn N
    J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationships between mutant prevention concentrations and mutation frequencies against enrofloxacin for avian pathogenic Escherichia coli isolates.
    Ozawa M; Asai T
    J Vet Med Sci; 2013; 75(6):709-13. PubMed ID: 23328636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
    Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
    Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations.
    Firsov AA; Portnoy YA; Strukova EN; Shlykova DS; Zinner SH
    Int J Antimicrob Agents; 2014 Oct; 44(4):301-5. PubMed ID: 25218155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure.
    Malik M; Hoatam G; Chavda K; Kerns RJ; Drlica K
    Antimicrob Agents Chemother; 2010 Jan; 54(1):149-56. PubMed ID: 19805561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Antimicrobial Activity of Colistin in Combination with Rifampin and Azithromycin against Escherichia coli Producing MCR-1.
    Li Y; Lin X; Yao X; Huang Y; Liu W; Ma T; Fang B
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.